An observational study in Neurotoxicity, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-16.
Sponsored by M.D. Anderson Cancer Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Neurotoxicity Syndromes with a site in United States — 6 open to participants now, 11 under way, 3 of them phase 3. Neurotoxicity Syndromes · United States.
Among the 76 studies in Neurotoxicity Syndromes with a site in United States, this one is the 8th largest by planned enrollment of the 23 observational ones that give a count, is the only one that started in 2024, is one of 23 observational ones, reaches primary completion later than 6 of the 10 other live ones, and was the 71st registered.
133 studies on the registry are indexed under Neurotoxicity Syndromes; 17 are open to participants now.
Browse Neurotoxicity Syndromes studies →6 of the 76 studies in Neurotoxicity Syndromes with a site in United States are open now. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
Beth Israel Deaconess Medical Center · Sites in United States
Ages 18+
Ka-Wai Ho · Sites in United States
Ages 18+
University of Chicago · Sites in United States
Ages 18+
Ellis Medicine · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 15 Neurotoxicity Syndromes studies recruiting now, 11 (73%) set no upper age limit and 1 (7%) stops at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 81 across 42 observational studies indexed under Neurotoxicity Syndromes.
Median enrollment 85 across the 52 interventional studies, 76 across the 23 observational. Of the 61 that completed or were terminated, 28 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 76 have an industry lead sponsor. The 10 most frequent:
M.D. Anderson Cancer Center is the lead sponsor of 3,051 studies on the registry; 580 are open to participants now.
Of its 614 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.
M.D. Anderson Cancer Center has 4 studies filed under Neurotoxicity Syndromes — fewer than ten, so there is no comparison to draw.
7 of the studies in Neurotoxicity Syndromes with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03089905Phase 3Murdoch Childrens Research InstituteA Study to Compare the Long-term Outcomes After Two Different Anaesthetics | 2026-12 |
| NCT00978458Phase 3Eastern Cooperative Oncology GroupRadiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma | 2026-12-31 |
| NCT06950190Phase 3Ellis MedicineEvaluating Cognitive Changes on Patients in Chemotherapy (ECCPC) | 2027-02-20 |
| NCT06144151M.D. Anderson Cancer CenterA Pilot Study for Pupillary Assessment to Predict CAR-T Related Neurotoxicity | 2027-04-01 |
| NCT07767981University of ChicagoMicrobiome Determinants of Adverse Effects of Stereotactic Radiosurgery | 2027-08-05 |
Add all 7 to your calendar (.ics) → With an account.
Among the 76 studies in Neurotoxicity Syndromes with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To learn about the relationship between changes in pupil size and reactivity and the start of neurological side effects in patients after receiving CAR-T cell therapy.
Primary Objective:
To assess the association between the status of NPi drop from baseline (prior to CAR T-cell infusion) to the lowest NPi post Axi-cel (CD19 CAR-T cell) infusion and the status of immune effector cell-associated neurotoxicity onset within 10 days post CD19 CAR-T cell infusion.
Secondary Objective:
To evaluate the largest absolute difference in NPi between two eyes (∆ NPi) and assess its association with severity of clinical symptoms as measured by Immune Effector Cell Encephalopathy (ICE) and or radiographic / EEG findings
Exploratory Objective:
To assess the feasibility and safety of a pupillometer use in patient treated with Axi-cel therapy.
MD Anderson Cancer Center
Inclusion Criteria:
To be considered eligible for study participation, patient will satisfy all relevant inclusion criteria and none of the exclusion criteria.
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The pupilometer is a non-invasive device which will be placed in front of your eyes, one at a time. It looks like a handheld spotlight or scanner, with a small plastic guide sticking out that will be placed against your cheek to help keep the device in place during the scan. It will not touch your eye. Both your left and right eyes will be measured with the device each time. Scanning with the pupilometer will take less than 5 minutes total for both eyes.
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Time frame: Through study completion; an average of 1 year.
Started Feb 2024 (actual). Primary completion is estimated for Apr 2027, 37 months after the start.
Of 20 observational studies under Neurotoxicity Syndromes, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 18. This study's planned 37 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.